Skip to content

Other psychological and non-drug therapies

TL;DR — Two non-CBT approaches have genuinely surprising GAD-specific evidence. Metacognitive therapy beat CBT head-to-head in a three-arm RCT (n=81 randomised from 246 assessed): recovery 65% vs 38%, mean difference 9.762 (95% CI 2.679–16.845, p=0.004), maintained at 2 years (Nordahl 2018, PMID 30294448), and at 9-year follow-up recovery was 57% (MCT) vs 38% (CBT) with GAD re-diagnosis in 9.5% vs 23.1% (Solem 2021, PMID 34520637). Mindfulness-based stress reduction was non-inferior to escitalopram in a pre-specified non-inferiority RCT of 276 adults with anxiety disorders (CGI-S difference −0.07, 95% CI −0.38 to 0.23; margin −0.495), with study-related adverse events in 78.6% of the escitalopram arm vs 15.4% of the MBSR arm and zero adverse-event dropouts from MBSR (Hoge 2023, PMID 36350591, NCT03522844) — though that trial pooled anxiety disorders, so it is not a GAD-specific result. Short-term psychodynamic psychotherapy matched CBT on the HAM-A at post-treatment and at 12 months, while CBT was superior on trait anxiety and worry (Leichsenring 2009, PMID 19570931; Salzer 2011, PMID 21878162). Everything else here — ACT, emotion regulation therapy, exercise, acupuncture, phytoceuticals — is either small, feasibility-stage, or evidenced only in analogue/subclinical samples.

Metacognitive therapy: the strongest non-CBT signal

MCT targets meta-worry and beliefs about worry rather than worry content (mechanism and models).

Outcome MCT CBT Waitlist Source
n randomised 32 28 21 Nordahl 2018, PMID 30294448 (NCT00426426)
Post-treatment difference MCT superior, MD 9.762 (95% CI 2.679–16.845), p=0.004 — — Nordahl 2018, PMID 30294448
Recovery, post-treatment 65% 38% — Nordahl 2018, PMID 30294448
Recovery, 9 years (completers, 39/60 = 65% response) 57% 38% — Solem 2021, PMID 34520637
Sustained recovery from post-treatment to 9 years 43% (plus 14% achieving recovery later) 13% (plus 25% later) — Solem 2021, PMID 34520637
Re-diagnosed with GAD at 9 years 9.5% 23.1% — Solem 2021, PMID 34520637

Three caveats belong with these numbers. (i) The trial is small — 81 randomised of 246 assessed — and the 9-year follow-up retained 39 of 60. (ii) The authors of both the MCT and CBT protocols were investigators on the trial and declare royalty interests (Nordahl 2018, PMID 30294448); allegiance effects in psychotherapy trials are a known bias source. (iii) The result has not been replicated by an independent group at scale [unverified as of 2026-09-02]. Against that, the direction is consistent with the network meta-analysis in which third-wave CBTs performed at least as well as classical CBT (SMD −0.76 vs −0.74) (Papola 2024, PMID 37851421), and with the model-level evidence that meta-worry is the most influential path in the metacognitive model (Nordahl 2023, PMID 36321682).

A primary-care pilot RCT compared intolerance-of-uncertainty therapy against MCT directly (Af Winklerfelt Hammarberg 2023, PMID 37315099) — the two mechanism-derived protocols against each other, in the setting where most GAD is actually managed.

Mindfulness and acceptance-based approaches

Intervention Design Result Source
MBSR vs escitalopram 10–20 mg, 8 weeks Randomised non-inferiority trial, 276 randomised / 208 per-protocol, 3 urban US academic centres, blinded raters; anxiety disorders (not GAD-only) CGI-S reduction 1.35 (MBSR) vs 1.43 (escitalopram); between-group −0.07 (95% CI −0.38 to 0.23; p=0.65) — non-inferior. Adverse events: 78.6% (escitalopram) vs 15.4% (MBSR); AE dropouts 8% vs 0% Hoge 2023, PMID 36350591 (NCT03522844) — pooled anxiety disorders
Same trial, mechanism Anxiety-potentiated startle Attenuated after both escitalopram and mindfulness meditation Hoge 2024, PMID 37331547
Same trial, secondary analyses Work performance; self-compassion; in-person vs remote delivery Reported separately Oft 2024, PMID 39134156; Baker 2026, PMID 41759355; Hoge 2025, PMID 40324655
Mindfulness meditation, GAD-specific RCT of mindfulness meditation for GAD, effects on anxiety and stress reactivity GAD-specific evidence predating TAME Hoge 2013, PMID 23541163
ACT vs CBT, older adults 16 older primary-care patients (ACT 7, CBT 9) Feasibility: no ACT dropouts; worry and depression improved Wetherell 2011, PMID 21292059
ACT for treatment-resistant late-life GAD (FACTOID) Uncontrolled feasibility study, up to 16 sessions, adults ≥65 Feasibility/acceptability co-primary outcomes; not an efficacy trial Gould 2021, PMID 34542399; Gould 2021, PMID 33852722
Acceptance-based behaviour therapy vs applied relaxation RCT, mediation analysis Reductions in experiential avoidance mediated change in symptoms and quality of life Eustis 2016, PMID 27718414
Acceptance-based therapy (network position) Bayesian NMA, 56 studies, 4,388 participants Short- and long-term efficacy "notable" among third-wave CBTs Dai 2025, PMID 40367584

The MBSR-vs-escitalopram result is the most policy-relevant number in this section and the most frequently over-read. It is a non-inferiority finding in a mixed anxiety-disorder sample; it does not establish that MBSR equals escitalopram in GAD specifically, and the trial's own registration and design papers frame it as a treatment-access question (Hoge 2020, PMID 32087339). Its adverse-event asymmetry, however, is GAD-relevant regardless of disorder mix.

Motivational interviewing as an enhancement to CBT

The one enhancement strategy with an allegiance-controlled trial in severe GAD — therapists nested within treatment group and supervised separately by experts in each approach (Westra 2016, PMID 26985729):

Outcome CBT alone (n=43) MI–CBT (4 MI sessions then 11 integrated sessions; n=42)
Pre- to post-treatment difference No between-group difference —
Worry decline over follow-up — Steeper (γ=−0.13, p=0.03)
General distress reduction over follow-up — Steeper (γ=−0.12, p=0.01)
Odds of no longer meeting GAD criteria at 12 months reference ~5 times higher
Dropout 23% 10% (p=0.09)

Two features make this trial informative. The advantage appeared over follow-up rather than at post-treatment, and estimated between-therapist effects were negligible; this reduces but does not eliminate therapist-level confounding or prove that the protocol alone caused the difference. Mediation analyses from the same programme implicated client interpersonal impacts and responsivity to in-session resistance (Constantino 2018, PMID 28337945; Constantino 2019, PMID 28580884; Aviram 2016, PMID 27031326), while an earlier pilot established feasibility (Westra 2009, PMID 19665347).

Acceptance- and mindfulness-based interventions, pooled

Across 23 RCTs and 1,815 adults with DSM-5 anxiety disorders, comparing ACT, MBCT and MBSR (PROSPERO CRD42017076810; Haller 2021, PMID 34650179):

  • Added to treatment as usual, all three produced short-term improvements in clinician- and patient-rated anxiety versus TAU alone.
  • Against CBT: ACT and MBCT were comparable; MBSR was significantly lower.
  • At 6 and 12 months, no significant differences from TAU or CBT remained.
  • Statistical heterogeneity was moderate to considerable; most studies were of unclear risk of bias; adverse events were reported insufficiently; and specific treatment effects exceeding placebo mechanisms "remain unclear" in the authors' words.

Set against the TAME trial's non-inferiority of MBSR to escitalopram (Hoge 2023, PMID 36350591), this is a useful corrective: in the pooled anxiety-disorder literature MBSR performs worse than CBT, while ACT and MBCT do not. A comparison against a drug and a comparison against CBT are different questions with different answers.

Psychodynamic and emotion-focused therapies

  • Short-term psychodynamic psychotherapy (STPP). 57 DSM-IV GAD patients randomised to CBT (n=29) or STPP (n=28), up to 30 manualised weekly sessions, HAM-A primary with blinded raters: both produced significant, large improvements with no significant difference on the primary outcome; CBT superior on trait anxiety, worry and depression (Leichsenring 2009, PMID 19570931). At 12 months both remained large and stable, still no primary-outcome difference, CBT still superior on trait anxiety and worry, and the depression difference no longer significant (Salzer 2011, PMID 21878162).
  • Emotion regulation therapy (ERT). 53 patients with primary GAD (43% comorbid MDD) randomised to ERT (n=28) or a modified attention control (n=25): ERT superior on GAD and MDD indicators, worry, rumination, comorbid severity, functional impairment and quality of life, with most effects exceeding conventions for a large effect and maintained at 9 months; hypothesised mediators (attentional, metacognitive, emotion-regulation) all mediated outcomes (Mennin 2018, PMID 29504794). This is one of the very few GAD trials designed around the comorbid-depression case rather than excluding it (comorbidity and primary care).
  • The Cochrane baseline. The 2007 Cochrane review of psychological therapies for GAD (25 studies, 1,305 participants) found that psychological therapies — all of them CBT — beat treatment as usual/waitlist for clinical response (RR 0.63, 95% CI 0.55–0.73), and noted that no study conducted longer-term assessment of CBT against TAU/WL (Hunot 2007, PMID 17253466). Nineteen years later the long-term evidence has improved only modestly (course, relapse and long-term outcome).

Exercise, complementary and biological non-drug approaches

Intervention Evidence Verdict
Yoga (Kundalini) 3-arm RCT, n=226 with primary GAD: response 54.2% vs 33.0% stress education (OR 2.46, 1.12–5.42; NNT 4.59); CBT 70.8% (OR 5.00; NNT 2.62); noninferiority of yoga vs CBT not established Efficacious but second-line (Simon 2021, PMID 32805013)
Resistance exercise training 8-week supervised RCT, 44 randomised, analogue (subclinical) GAD defined by PDSQ-GAD ≥6 and PSWQ ≥45: NNT 3 (95% CI 2–7) for AGAD remission; worry d=0.93 (0.13–1.73), anxiety d=0.71 (−0.08 to 1.49) Promising, but subclinical sample and n=27 in primary analysis (Gordon 2021, PMID 33321380)
Exercise, transdiagnostic Umbrella review of exercise across mental disorders Broad support at umbrella level, not GAD-specific (Solmi 2025, PMID 40043589)
Acupuncture vs sham 14 RCTs, 968 participants, GAD-specific: HAMA MD −2.71 (−4.17 to −1.25); GAD-7 MD −2.99 (−5.52 to −0.45); PSQI −2.83; cortisol SMD −0.33; evidence certainty low to very low for patient-reported outcomes, high heterogeneity Signal present, certainty poor (Jiang 2025, PMID 41312341)
Medicinal herbs Bayesian NMA, 29 trials, 12 herbs, HAMA endpoint: Silexan (lavender oil) MD −3.84 (95% CrI −6.31 to −1.34); kava MD −2.46 (−4.47 to −0.32) overall; Ginkgo biloba −4.63 and Withania somnifera −4.90 both from small trials The abstract's GAD-specific kava estimate is internally inconsistent (MD −0.17, 95% CrI −2.55 to −1.97), so that magnitude and its direction cannot be interpreted without correction (Zhang 2022, PMID 35378276)
Nutraceuticals/phytoceuticals guideline WFSBP/CANMAT taskforce, 31 academics, 15 countries; graded Recommended → Not Recommended The formal guideline layer for this category (Sarris 2022, PMID 35311615) — see literature/guidelines/REGISTRY.md
Non-invasive brain stimulation Systematic review and network meta-analysis of NIBS for GAD Efficacy and acceptability assessed; see treatment-resistant GAD (Duan 2025, PMID 40203547)
Non-pharmacological interventions for insomnia in GAD Systematic evaluation and network meta-analysis Sleep is a plausible second target given the bidirectional link (Zhang 2025, PMID 41244878; Xue 2025, PMID 40318600)

How these compare with CBT

Papola's network meta-analysis is the only place all of these sit in one model, and its headline is that the differences among active psychotherapies are small: third-wave CBT −0.76, CBT −0.74, relaxation −0.59 vs treatment as usual, with overlapping intervals and no acceptability differences (Papola 2024, PMID 37851421). Against that background, the MCT head-to-head result (Nordahl 2018, PMID 30294448; Solem 2021, PMID 34520637) is an outlier that either identifies a genuinely better treatment or reflects a small single-centre trial with allegiance effects. Resolving that is one of this condition's most tractable open questions.

Open questions

  • Does metacognitive therapy's advantage over CBT survive independent replication with pre-registered allegiance controls? The existing evidence is one trial and its 9-year follow-up (Nordahl 2018, PMID 30294448; Solem 2021, PMID 34520637).
  • Is MBSR non-inferior to an SSRI in GAD specifically, or only in mixed anxiety samples? TAME pooled disorders (Hoge 2023, PMID 36350591).
  • What is kava's GAD-specific effect? The PubMed abstract's point estimate lies outside its own credible interval (Zhang 2022, PMID 35378276); the source must be corrected before a disorder-specific conclusion is possible.
  • Does resistance exercise work in diagnosed GAD? The RCT evidence is in analogue GAD (Gordon 2021, PMID 33321380).
  • Does the follow-up-only advantage seen for both MI-augmented CBT (Westra 2016, PMID 26985729) and metacognitive therapy (Solem 2021, PMID 34520637) point to a shared mechanism operating after treatment ends?
  • Should emotion regulation therapy be the default when GAD and depression co-occur? It is the only GAD protocol trialled with comorbidity deliberately included (Mennin 2018, PMID 29504794).

References

  1. Nordahl HM, et al. Metacognitive therapy versus cognitive-behavioural therapy in adults with generalised anxiety disorder. BJPsych Open. 2018;4:393-400. PMID 30294448
  2. Solem S, et al. Metacognitive therapy versus cognitive-behavioral therapy in adults with generalized anxiety disorder: A 9-year follow-up study. Brain Behav. 2021;11:e2358. PMID 34520637
  3. Nordahl H, et al. An empirical test of the metacognitive model of generalized anxiety disorder. Scand J Psychol. 2023;64:263-267. PMID 36321682
  4. Af Winklerfelt Hammarberg S, et al. Intolerance-of-uncertainty therapy versus metacognitive therapy for generalized anxiety disorder in primary health care: A randomized controlled pilot trial. PLoS One. 2023. PMID 37315099
  5. Hoge EA, et al. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023;80:13-21. PMID 36350591
  6. Hoge EA, et al. Treatment for anxiety: Mindfulness meditation versus escitalopram (TAME): Design of a randomized, controlled non-inferiority trial. Contemp Clin Trials. 2020. PMID 32087339
  7. Hoge EA, et al. Attenuation of Anxiety-Potentiated Startle After Treatment With Escitalopram or Mindfulness Meditation in Anxiety Disorders. Biol Psychiatry. 2024. PMID 37331547
  8. Hoge EA, et al. A randomized controlled trial comparing mindfulness to escitalopram for anxiety: in-person and remote, synchronous delivery pre and post COVID-19 pandemic. J Affect Disord. 2025. PMID 40324655
  9. Oft AC, et al. Effect of meditation or escitalopram on work performance in patients with anxiety disorders. J Affect Disord. 2024. PMID 39134156
  10. Baker AW, et al. Effects of MBSR and escitalopram on self-compassion in anxiety disorders. J Psychiatr Res. 2026. PMID 41759355
  11. Hoge EA, et al. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013. PMID 23541163
  12. Wetherell JL, et al. Acceptance and Commitment Therapy for generalized anxiety disorder in older adults: a preliminary report. Behav Ther. 2011;42:127-34. PMID 21292059
  13. Gould RL, et al. Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: the FACTOID feasibility study. Health Technol Assess. 2021;25:1-150. PMID 34542399
  14. Gould RL, et al. Acceptance and commitment therapy for late-life treatment-resistant generalised anxiety disorder: a feasibility study. Age Ageing. 2021;50:1751-1761. PMID 33852722
  15. Eustis EH, et al. Reductions in experiential avoidance as a mediator of change in symptom outcome and quality of life in acceptance-based behavior therapy and applied relaxation. Behav Res Ther. 2016. PMID 27718414
  16. Leichsenring F, et al. Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry. 2009;166:875-81. PMID 19570931
  17. Salzer S, et al. Long-term effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in generalized anxiety disorder: 12-month follow-up. Can J Psychiatry. 2011;56:503-8. PMID 21878162
  18. Mennin DS, et al. A randomized controlled trial of emotion regulation therapy for generalized anxiety disorder with and without co-occurring depression. J Consult Clin Psychol. 2018;86:268-281. PMID 29504794
  19. Hunot V, et al. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007;2007:CD001848. PMID 17253466
  20. Simon NM, et al. Efficacy of Yoga vs Cognitive Behavioral Therapy vs Stress Education for the Treatment of Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78:13-20. PMID 32805013
  21. Gordon BR, et al. Resistance exercise training among young adults with analogue generalized anxiety disorder. J Affect Disord. 2021;281:153-159. PMID 33321380
  22. Solmi M, et al. Exercise as a transdiagnostic intervention for improving mental health: An umbrella review. J Psychiatr Res. 2025. PMID 40043589
  23. Jiang H, et al. Efficacy of acupuncture versus sham acupuncture on generalized anxiety disorder: a meta-analysis of randomized controlled trials. Front Neurol. 2025;16:1682400. PMID 41312341
  24. Zhang W, et al. Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis. Pharmacol Res. 2022;179:106204. PMID 35378276
  25. Sarris J, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The WFSBP and CANMAT Taskforce. World J Biol Psychiatry. 2022;23:424-455. PMID 35311615
  26. Duan N, et al. Evaluating the efficacy and acceptability of non-invasive brain stimulation for generalized anxiety disorder: a systematic review and network meta-analysis. Psychiatry Res Neuroimaging. 2025. PMID 40203547
  27. Zhang B, et al. Efficacy of non-pharmacological interventions for alleviating insomnia in individuals with generalized anxiety disorder: systematic evaluation and network meta-analysis. Front Psychiatry. 2025. PMID 41244878
  28. Xue Y, et al. Sleep disturbances in generalized anxiety Disorder: The central role of insomnia. Sleep Med. 2025;132:106545. PMID 40318600
  29. Papola D, et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024;81:250-259. PMID 37851421
  30. Dai X, et al. (Third-wave) cognitive behavioral therapy for generalized anxiety disorder in adults: A systematic review and Bayesian network meta-analysis. J Psychiatr Res. 2025;187:134-143. PMID 40367584
  31. Westra HA, et al. Integrating motivational interviewing with cognitive-behavioral therapy for severe generalized anxiety disorder: An allegiance-controlled randomized clinical trial. J Consult Clin Psychol. 2016;84:768-782. PMID 26985729
  32. Westra HA, et al. Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: a preliminary randomized controlled trial. J Anxiety Disord. 2009;23:1106-17. PMID 19665347
  33. Constantino MJ, et al. Client interpersonal impacts as mediators of long-term outcome in cognitive-behavioral therapy integrated with motivational interviewing for generalized anxiety disorder. Psychother Res. 2018;28:861-872. PMID 28337945
  34. Constantino MJ, et al. Specific and common processes as mediators of the long-term effects of cognitive-behavioral therapy integrated with motivational interviewing for generalized anxiety disorder. Psychother Res. 2019;29:213-225. PMID 28580884
  35. Aviram A, et al. Responsive management of early resistance in cognitive-behavioral therapy for generalized anxiety disorder. J Consult Clin Psychol. 2016;84:783-794. PMID 27031326
  36. Haller H, et al. A systematic review and meta-analysis of acceptance- and mindfulness-based interventions for DSM-5 anxiety disorders. Sci Rep. 2021;11:20385. PMID 34650179
  37. Newman MG, et al. Psychotherapeutic treatments for generalized anxiety disorder: cognitive and behavioral therapies, enhancement strategies, and emerging efforts. Expert Rev Neurother. 2022;22:751-770. PMID 36107159